安迪苏30亿定增获批拟扩产补流 两大产品营收齐增半年盈利7.4亿

Core Viewpoint - The approval of Andy Su's 3 billion yuan private placement aims to enhance production capacity and support sustainable development projects, reflecting the company's growth strategy in the animal nutrition sector [1][2]. Fundraising and Business Expansion - Andy Su plans to raise up to 3 billion yuan through a private placement to expand production capacity and supplement working capital [2]. - The funds will be allocated to functional products, special products, and sustainable development projects, with 1.743 billion yuan specifically earmarked for a solid methionine project [2][3]. - The company categorizes its main products into functional products (including methionine and vitamins) and special products (including feed additives) [2]. Market Demand and Growth - The global demand for methionine is projected to reach 1.7 million tons by 2024, with a compound annual growth rate (CAGR) of 4.4%, while China's demand is expected to grow from 280,000 tons in 2019 to 450,000 tons by 2024, with a CAGR of 10% [3]. - The company anticipates strong market absorption for its new production capacity due to this growing demand [3]. Financial Performance - In the first half of 2025, Andy Su reported a revenue increase of 17.23% to 8.512 billion yuan and a net profit increase of 21.82% to 740 million yuan [4]. - The sales of methionine continued to grow, driven by increased market penetration, with a 16% year-on-year increase in sales volume [4]. - The special products segment also saw a revenue increase of 9% to 2.04 billion yuan, supported by strong sales growth in ruminant and pig products [4]. Research and Development - The company is committed to increasing R&D investments in green production, biotechnology, and digital services, with R&D expenses reaching 172 million yuan in the first half of 2025 [5]. - Andy Su operates five global R&D centers with over 300 employees dedicated to research and innovation, which are crucial for supporting its dual pillar strategy [5].